Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate
Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate
Ocugen獲批加入治療Stargardt病藥物候選劑高劑量研究
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊